Last reviewed · How we verify

GM-CSF, IFN alpha and IL-2

Kidney Cancer Research Bureau · Phase 2 active Small molecule Quality 0/100

GM-CSF, IFN alpha and IL-2 is a Small molecule drug developed by Kidney Cancer Research Bureau. It is currently in Phase 2 development.

At a glance

Generic nameGM-CSF, IFN alpha and IL-2
SponsorKidney Cancer Research Bureau
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GM-CSF, IFN alpha and IL-2

What is GM-CSF, IFN alpha and IL-2?

GM-CSF, IFN alpha and IL-2 is a Small molecule drug developed by Kidney Cancer Research Bureau.

Who makes GM-CSF, IFN alpha and IL-2?

GM-CSF, IFN alpha and IL-2 is developed by Kidney Cancer Research Bureau (see full Kidney Cancer Research Bureau pipeline at /company/kidney-cancer-research-bureau).

What development phase is GM-CSF, IFN alpha and IL-2 in?

GM-CSF, IFN alpha and IL-2 is in Phase 2.

Related